knowledge -WSS

knowledge

author：leisure time 2025-09-30 18:00:30 - browse：3

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Take antibiotics after sex, CDC recommends for certain risk groups

WSS

An outdated Medicare rule harms dementia patients with anxiety

CMS got Medicare Advantage quality rating wrong, judge rules

Study: Black kids more likely to die after surgery than white kids

Congress needs to close a vaccine

Medicare Advantage 2025 payments will dip, Biden administration says

Pancreatic cancer is often deadly, but new discoveries are raising hope

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Hundreds died while taking an arthritis drug, but nobody alerted patients

Hepatitis C has a cure — but many Americans still lack access to it

Senators tussle over abortion against the backdrop of a presidential campaign

Medical leaders decry Supreme Court decision on affirmative action

BD to buy Edwards patient monitoring unit for $4.2 billion

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Four alarming medical procedures we’re glad history forgot

Novavax promises a turnaround & Lilly roils the obesity market

Scientific mystery highlights the blind spots in genomics databases

knowledge

Take antibiotics after sex, CDC recommends for certain risk groups

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Harvard scientists, with Google, unveil the most detailed brain map ever

FTC loses bid to block Novant's North Carolina hospital merger

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Senators tussle over abortion against the backdrop of a presidential campaign

knowledge

leisure time

knowledge

focus